GlassScriptPhysician profile
Rajeev Nagpal
NPI 1396731329
$6,301.01
in general payments reported to CMS, 2019-2025
25 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what 83% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $281 · 2021: $571 · 2022: $602 · 2023: $1,612 · 2024: $1,741 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,487.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,653.77 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $861.27 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $806.51 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Qol Medical, LLC | $668.89 | 2019-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $565.61 | 2023-2025 | |
| Mirum Pharmaceuticals, INC. | $548.37 | 2022-2025 | Livmarli |
| Sandoz INC. | $177.14 | 2023-2024 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $155.88 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $152.23 | 2024-2025 | Bylvay |
| Janssen Biotech, INC. | $103.04 | 2024-2025 | Tremfya, Stelara |
| Amgen INC. | $102.13 | 2023 | Amjevita |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.74 | 2019 | |
| Biocon Biologics INC | $89.23 | 2023-2025 | Hulio, Yesintek |
| Fresenius Kabi USA, LLC | $48.59 | 2023 | Idacio |
| Meridian Bioscience INC. | $46.34 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $37.20 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $31.87 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.12 | 2023-2024 | Cyltezo |
| Capsovision, INC. | $28.01 | 2024 | Capsocam Plus |
| Redhill Biopharma INC. | $24.90 | 2020 | |
| Alfasigma USA, INC. | $15.89 | 2020 | |
| Travere Therapeutics, INC. | $14.74 | 2019 | |
| Boston Scientific Corporation | $14.15 | 2019 | |
| Horizon Therapeutics Plc | $12.81 | 2022 | |
| Echosens North America, INC. | $12.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Nagpal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.